Merck says experimental RSV treatment protected infants in trial, paving way for potential approvalMerck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season.[Collection]

Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season.https://www.cnbc.com/2024/10/17/merck-says-experimental-rsv-treatment-protected-infants-in-trial.html